Tislelizumab in Combination With Sitravatinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Stopped Due to safety risks and unfavorable risk-benefit assessment results, the sponsor has decided to voluntarily terminate the study.

Conditions

• Non-Small Cell Lung Cancer (NSCLC)

Interventions

• DRUG: Tislelizumab
• DRUG: Docetaxel
• DRUG: Sitravatinib

Sponsor

BeiGene